Takeda R&D Day 2024 Focus on Late-stage Pipeline & Market Opportunity

from the beginning

Opening

@

@

A Global, Innovation-driven Biopharmaceutical Company

@

@

@

@

R&D Strategy and Pipeline Highlights

@

@

@

@

@

@

@

@

@

@

@

@

Neuroscience: Deep-dive on Orexin Franchise

@

@

• Leading Orexin Franchise

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

• TAK-360 and beyondAdditional assets/indications

@

@

@

• Orexin Franchise Market Opportunity

@

@

@

@

@

@

@

@

@

Gastrointestinal & Inflammation (GI&I): Deep-dive on Zasocitinib, Rusfertide, Mezagitamab, and Fazirsiran

@

@

• Zasocitinib (TAK-279) Next-generation TYK2 Inhibitor, potential to be the 1st choice advanced therapy

@

@

@

@

@

@

@

@

@

@

@

@

@

@

@

• Zasocitinib Market Opportunity

@

@

@

@

@

@

@

@

@

• Rusfertide: Advancing Polycythemia Vera (PV) Treatment for Superior Hematocrit Control

@

@

@

@

@

@

• Rusfertide Market Opportunity

@

@

@

• Mezagitamab (TAK-079)Transformative Potential forChronic Auto-immuneDiseases

@

@

@

@

@

@

@

@

@

@

@

@

• Mezagitamab Market Opportunity

@

@

@

@

@

@

@

• Fazirsiran The potential of a transformative therapy for patients living with Alpha-1 Antitrypsin Deficiency Liver Disease (AATD-LD)

@

@

@

@

@

@

@

@

@

• Fazirsiran Market Opportunity

@

@

@

@

@

@

Oncology: Deep dive on Elritercept - newly announced BD deal

@

@

@

@

• ElriterceptPotentially best-in-class activin inhibitor for treatment of anemia associated with hematologic diseases, including myelodysplastic syndromes (MDS) & myelofibrosis (MF)

@

@

@

@

@

@

@

@

• Elritercept Commercial Opportunity

@

@

@

@

@

Q&A SESSION

• Q&A 1

• Q&A 2

• Q&A 3

• Q&A 4

• Q&A 5

• Q&A 6

• Q&A 7

• Q&A 8

• Q&A 9